tert-butyl N-[(2R)-2-hydroxycyclopentyl]carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[(2R)-2-hydroxycyclopentyl]carbamate
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.26
• InChiKey: CGZQRJSADXRRKN-BRFYHDHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20190031664A1

  公开（公告）日：2019-01-31

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2以及治疗TYK2介导的疾病的方法。
• TYK2 inhibitors and uses thereof
  申请人：Nimbus Lakshmi, Inc.

  公开号：US10562906B2

  公开（公告）日：2020-02-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了用于抑制 TYK2 和治疗 TYK2 介导的疾病的化合物、其组合物和使用方法。
• Bicyclic heterocycles as FGFR4 inhibitors
  申请人：Incyte Corporation

  公开号：US10851105B2

  公开（公告）日：2020-12-01

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

  本发明涉及双环杂环及其药物组合物，它们是 FGFR4 酶的抑制剂，可用于治疗 FGFR4 相关疾病，如癌症。
• BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170320877A1

  公开（公告）日：2017-11-09

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：NIMBUS LAKSHMI INC

  公开号：WO2019023468A1

  公开（公告）日：2019-01-31

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.